Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

BACKGROUND: New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: We conducted a phase 3, double-blind...

Descripción completa

Detalles Bibliográficos
Autores principales: Jayk Bernal, Angélica, Gomes da Silva, Monica M., Musungaie, Dany B., Kovalchuk, Evgeniy, Gonzalez, Antonio, Delos Reyes, Virginia, Martín-Quirós, Alejandro, Caraco, Yoseph, Williams-Diaz, Angela, Brown, Michelle L., Du, Jiejun, Pedley, Alison, Assaid, Christopher, Strizki, Julie, Grobler, Jay A., Shamsuddin, Hala H., Tipping, Robert, Wan, Hong, Paschke, Amanda, Butterton, Joan R., Johnson, Matthew G., De Anda, Carisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693688/
https://www.ncbi.nlm.nih.gov/pubmed/34914868
http://dx.doi.org/10.1056/NEJMoa2116044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693688/
https://www.ncbi.nlm.nih.gov/pubmed/34914868
http://dx.doi.org/10.1056/NEJMoa2116044

Ejemplares similares